Hologic (NASDAQ:HOLX), A drop of 307,162 shares or 5% was seen in the short interest of Hologic, Inc.. Even as the interest dropped from 6,166,063 shares on May 31,2016 to 5,858,901 shares on June 15,2016, the days to cover came in at 2. The updated interest stood at 2.1% of the stocks floats. The stock has seen an average daily volume of 3,010,797 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Hologic (NASDAQ:HOLX): The stock opened at $34.33 on Friday but the bulls could not build on the opening and the stock topped out at $34.85 for the day. The stock traded down to $33.96 during the day, due to lack of any buying support eventually closed down at $34.11 with a loss of -4.24% for the day. The stock had closed at $35.62 on the previous day. The total traded volume was 6,377,279 shares.
The company shares have dropped -9.35% from its 1 Year high price. On Aug 18, 2015, the shares registered one year high at $43.00 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $33.98 and the 200 Day Moving Average price is recorded at $35.25.
Stocks of Hologic (NASDAQ:HOLX) rallied by 0.89% during the past week but lost 0.87% on a 4-week basis. In the past week, the company has outperformed the S&P 500 by 2.56% and the outperformance has advanced to 2.13% for the last 4 weeks period.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.